POLYCYTHEMIA VERA (PV) – MPN Research Foundation
Distribution of driver mutations in polycythemia vera (PV), essential... | Download Scientific Diagram
JAK INHIBITORS AND JAK2 MUTATION: WHAT'S THE CONNECTION? – MPN Research Foundation
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation | PNAS
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications | Leukemia
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders | Nature Reviews Cancer
JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results - The ASCO Post
Polycythemia Vera
Pathophysiology of thrombosis in myeloproliferative neoplasms | Haematologica
Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations | Haematologica
POLYCYTHEMIA VERA (PV) – MPN Research Foundation
Pathogenesis of myeloproliferative neoplasms - ScienceDirect
Polycythemia vera jak2
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Leukemia
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders | NEJM
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views | Leukemia
Cureus | JAK2 and TET2 Mutation in Polycythemia Vera
JAK2-A Short Review – ProPath
JAK2-A Short Review – ProPath
Immunotherapy and polycythemia vera
JAK2 Reflex for Polycythemia with Interpretation
References in Evaluation of “Increased” Hemoglobin in the JAK2 Mutations Era: A Diagnostic Algorithm Based on Genetic Tests - Mayo Clinic Proceedings
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management - Tefferi - 2020 - American Journal of Hematology - Wiley Online Library
